Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.
about
Prevention and treatment of bone fragility in cancer patientCancer treatment-related bone disease.Aromatase inhibitors-induced bone loss in early breast cancer.Increased fracture rate in women with breast cancer: a review of the hidden risk.Management options of breast cancer related osteoporosis.Medication-induced osteoporosis: screening and treatment strategiesZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massBone health history in breast cancer patients on aromatase inhibitors.Prevention of bone metastases and management of bone health in early breast cancer.NCCN Task Force Report: Bone Health in Cancer Care.Cancer Treatment-Induced Bone Loss in women with breast cancerCancer treatment-related bone loss: a review and synthesis of the literature.Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws.A study to evaluate the cause of bone demineralization in gynecological cancer survivors.Practical guidance for the management of aromatase inhibitor-associated bone loss.Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Emerging drugs for the management of cancer treatment induced bone loss.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGAromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.Aging and osteoporosis in breast and prostate cancer.Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.Skeletal manifestations of treatment of breast cancer on premenopausal women.Osteoporosis after stem cell transplantation.A review of osteoporosis management in younger premenopausal women.Bone health care for patients with prostate cancer receiving androgen deprivation therapy.Adverse skeletal effects of drugs - beyond Glucocorticoids.Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use.Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors.Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.Bone health management of Australian breast cancer survivors receiving hormonal therapy.Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.Evaluation and management of skeletal disease in cancer care.Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.Q57133506
P2860
Q26775765-8CDFDB18-68CC-482D-B6C5-A19F37CB15D9Q30438185-3E65E7F5-D4A4-4020-890D-BE643E07DD79Q33752867-2BDC7E2C-1038-4CFC-8765-630749E64947Q34004925-E2C6533D-2EAF-49AD-8F48-AB588AA23E6DQ34230292-F4FD8E9D-B0E1-4806-8140-420CDA872902Q34389358-743CA56E-6E6D-4EB8-B714-908A8CCA398CQ34389524-31CDE44B-7302-4034-9AD5-9B6E3E12D6C3Q34421028-CF56EE89-E0AC-4ECC-BEFB-AA186076885DQ34613485-DD9C3CE4-227E-4B25-BD36-2B2A7079A4D6Q34617936-0B065F3F-7798-4E73-B437-5FA3D7AAFE26Q35632616-3787DD1A-D72C-4489-82C6-2ED22442B71DQ36410640-4C6FF250-C677-40F2-949B-E54F460837A9Q36421443-2C56130F-41D9-4D22-B54E-FD115D412DD5Q36804512-CDC04340-4AB5-4F4F-954E-818F9057EB37Q37151578-99961CEE-DB3D-4A07-859D-576D66E60912Q37350988-68902E6A-C195-4CBD-954E-FEFDF7D1FBDCQ37727235-09D036AC-30D3-4DF5-B308-D2C2DC313E3BQ37742180-24BAC158-1011-46D2-8D3F-D0B6ECB53958Q37830371-038CC8E2-6B2A-4438-AFEF-2B21A9F07A1AQ37872146-393664A7-3090-461C-8758-8B849482D37CQ37952851-31211767-F4CD-4422-BFE4-C21DE8A9CD89Q38152661-CDD74730-12B3-42D4-84A2-6BEF46C33A38Q38160758-F8D4938B-9223-4F1C-AE71-130496BDC385Q38170408-41B530C0-4469-470A-B866-02354EC7DD66Q38207463-A793DAA3-DF35-47DC-B922-0AF62EA9AA7AQ38231316-F93B2D19-C72C-44E0-B89E-C689B025F336Q38493690-8FE86AE2-8FE0-4BC0-B716-B28264E366EEQ38612952-DBC0D11D-4725-443D-B2B7-5C3CCA537A12Q39458785-F0B0BF17-4E6C-4B21-B7D0-6F521E4AF92CQ41391048-29C10F70-F225-4FEC-AFB3-9675F9BBB78AQ42363605-A43E94E6-6711-484D-8B16-398EA23CAB9EQ45028659-66869A98-5BD7-4467-86AA-DB4F4DCA04DCQ48168052-0CF5CB4E-55A4-4FBF-AA4F-094D5720F8C5Q50070694-AAA4EB42-A4A4-410B-A5AC-E29E59265FD1Q51393764-41849098-D434-400E-8E2F-83AD82F08F65Q53136867-10334400-A813-43CD-91BE-8A5896A418A1Q57133506-397E75FA-5793-4F13-9A6F-EF7602EDA45B
P2860
Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Management of cancer treatment ...... aper of the Belgian Bone Club.
@en
type
label
Management of cancer treatment ...... aper of the Belgian Bone Club.
@en
prefLabel
Management of cancer treatment ...... aper of the Belgian Bone Club.
@en
P2093
P1476
Management of cancer treatment ...... aper of the Belgian Bone Club.
@en
P2093
Bergmann P
Devogelaer JP
Goemaere S
Kaufman JM
Reginster JY
Rozenberg S
P2860
P2888
P304
P356
10.1007/S00198-007-0439-4
P407
P577
2007-08-10T00:00:00Z